J. Xiao

发表

Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma.

J. Xu, Zonghai Li, Yingyi Zhang, 2019, Journal of Clinical Oncology.

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

Zonghai Li, Zhi Peng, Xiaotian Zhang, 2022, Nature Medicine.

A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials

Min Yang, Zonghai Li, J. Wan, 2022, Haematologica.

Low Dose of Human scFv-Derived BCMA-Targeted CAR-T Cells Achieved Fast Response and High Complete Remission in Patients with Relapsed/Refractory Multiple Myeloma

Min Yang, Jie Jin, Zonghai Li, 2018, Blood.

Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Zonghai Li, Z. Cai, Wenming Chen, 2021, Blood.

Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma

Z. Cai, Zonghai Li, Wenming Chen, 2020 .

Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report

K. Yu, Wenjun Yang, Zonghai Li, 2022, Frontiers in Immunology.

Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results

W. Wang, B. Bu, Daishi Tian, 2023, Journal of the Neurological Sciences.

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Min Yang, Zonghai Li, S. Hao, 2019, Blood.

Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.

T. Liang, P. Zhao, W. Fang, 2021 .

Association between P2Y12 inhibitor reloading and in-hospital outcomes for patients with non-ST-segment elevation acute coronary syndrome already on chronic P2Y12 receptor inhibitors therapy in China: findings from the CCC–ACS (improving care for cardiovascular disease in China-acute coronary syndro

Xia Li, Yulan Zhao, Zhenyu Yang, 2023, European Journal of Medical Research.

Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma

Min Yang, Jie Jin, Zonghai Li, 2020 .

Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Zonghai Li, Z. Cai, Wenming Chen, 2020, Blood.